Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity - Additional Information (Detail)

v3.22.4
Stockholders' Equity - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Class of Stock [Line Items]    
Number of common stock shares withheld 502,005  
Exercise of warrants   $ 2,279
Stock-based compensation expense $ 19,115 40,065
Common Stock [Member]    
Class of Stock [Line Items]    
Number of common stock shares withheld 502,005  
Exercise of warrants   $ 2,279
Exercise of warrants issued, shares for cash consideration   252,218
Aggregate exercise of warrants issued, shares   23,050
Issued warrants to purchase shares upon exercises   26,000
Shares issued to outside service provider, shares   15,828
Common Stock [Member] | March 2022 Acquisition [Member]    
Class of Stock [Line Items]    
Business acquisition, shares issued or issuable 116,550  
Common Stock [Member] | Pandologic Ltd [Member]    
Class of Stock [Line Items]    
Business acquisition, shares issued or issuable 352,330  
Common Stock [Member] | General and Administrative Expense [Member]    
Class of Stock [Line Items]    
Stock-based compensation expense   $ 369
Common Stock and Employee Stock Purchase Plan [Member]    
Class of Stock [Line Items]    
Shares issued in connection with stock option exercise 1,382,091 1,176,984